



- (51) **International Patent Classification:**
A61K 31/4375 (2006.01) *C07D 471/14* (2006.01)
- (21) **International Application Number:**
PCT/US2015/064331
- (22) **International Filing Date:**
7 December 2015 (07.12.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/088,540 6 December 2014 (06.12.2014) US
- (71) **Applicant:** **INTRA-CELLULAR THERAPIES, INC.**
[US/US]; 430 East 29th Street, Suite 900, New York, NY 10016 (US).
- (72) **Inventors:** **LI, Peng**; c/o Intra-Cellular Therapies, Inc., 430 East 29th Street, Suite 900, New York, NY 10016 (US). **ZHENG, Hailin**; c/o Intra-Cellular Therapies, Inc., 430 East 29th Street, Suite 900, New York, NY 10016 (US). **SNYDER, Gretchen**; c/o Intra-Cellular Therapies, Inc., 430 East 29th Street, Suite 900, New York, NY 10016 (US). **WENNOGLE, Lawrence P.**; c/o Intra-Cellular Therapies, Inc., 430 East 29th Street, Suite 900, New York, NY 10016 (US).

York, NY 10016 (US). **HENDRICK, Joseph**; c/o Intra-Cellular Therapies, Inc., 430 East 29th Street, Suite 900, New York, NY 10016 (US).

(74) **Agent:** **HOXIE, Thomas**; Hoxie & Associates LLC, 75 Main Street, Suite 203, Millburn, New Jersey 07041 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) **Title:** ORGANIC COMPOUNDS

Figure 1

Brain cGMP levels (p<0.05 vs. control, ANOVA)



(57) **Abstract:** The present invention relates to novel PDE2 inhibitory compounds of Formula I as described above, their use as pharmaceuticals and pharmaceutical compositions comprising them.



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, **Published:**
GW, KM, ML, MR, NE, SN, TD, TG).

— *with international search report (Art. 21(3))*

ORGANIC COMPOUNDS

TECHNICAL FIELD

[0001] The present invention relates to PDE2 inhibitory compounds of Formula I
5 as described below, their use as pharmaceuticals and pharmaceutical compositions
comprising them. These compounds are useful e.g., in the treatment of PDE2-
mediated disorders such as anxiety, depression, autism spectrum disorder (ASD),
schizophrenia and cognitive impairment.

10 BACKGROUND OF THE INVENTION

[0002] PDE2 is a 105-KDa homodimer that is expressed in a wide variety of
tissues and cell types including brain (including hippocampus, striatum and prefrontal
cortex), heart, platelets, endothelial cells, adrenal glomerulosa cells and macrophages.
Although cGMP is the preferred substrate and effector molecule for this enzyme,
15 PDE2 hydrolyzes both cyclic adenosine monophosphate (cAMP) and cyclic
guanosine monophosphate (cGMP) and is thought to be involved in a number of
physiological processes. In particular, it has been shown that inhibition of nitric oxide
synthase (NOS), which reduces cGMP signaling, attenuates the behavioral effects of
the benzodiazepine chlordiazepoxide, an anxiolytic compound. Also, commercially-
20 available tool inhibitors of PDE2 such as Bay 60-7550 have been shown to increase
cyclic nucleotide levels in the brain and have significant anti-anxiety and anti-
depressant effects in normal and stressed rodents (Xu et al., *Eur. J. Pharmacol.* (2005)
518:40-46; Masood et al., *J. Pharmacol. Exp. Ther.* (2008) 326:369-379; Masood et
al., *JPET* (2009) 331:690-699; Xu et al., *Intl. J. Neuropsychopharmacol.* (2013)
25 16:835-847). Inhibition of PDE2 by Bay 60-7550 has also been shown to elevate
cGMP and cAMP levels in stimulated primary neuronal cultures in a dose responsive
manner; enhance LTP in hippocampal slice preparations in response to electrical
stimulation; enhance learning in novel object recognition animal model and a social
recognition task in rats; improve acquisition and consolidation phases of novel object
30 memory in age impaired rats; improve performance on object location and recognition
tasks when administered after training. Gomez et al., *Bioorg. Med. Chem. Lett.*
(2013) 23:6522-6527. Bay 60-7550 has also been shown to improve cognition and
memory function in rats through the enhancement of nNOS activity in the brain.

(Domek-Lopacinska et al. (2008) *Brain Res.* 1216:68-77). Therefore, PDE2 plays an important role in effective behaviors and cognitive function.


[0003] In addition to effective behavior and cognitive function, it has been observed that in endothelial cells, PDE2A mRNA and activity are highly induced in response to tumor necrosis factor- α stimulation in vitro. Selective inhibition of PDE2 activity with 9-(6-phenyl-2-oxohex-3-yl)-2-(3,4-dimethoxybenzyl)-purin-6-one (PDP) greatly alters the barrier function of endothelial cells, suggesting that PDE2 is likely to play an important role in regulating fluid and protein integrity of the circulatory system under pathological conditions. Therefore, PDE2 may be a good pharmacological target for sepsis or in more localized inflammatory responses.

[0004] In a recent study, PDE2 inhibition has also been shown to elicit pulmonary dilation, prevents pulmonary vascular remodeling and reduces the right ventricular hypertrophy characteristic of pulmonary hypertension, suggesting therapeutic potential of PDE2 inhibition in pulmonary hypertension. Bubb et al., "Inhibition of Phosphodiesterase 2 Augments cGMP and cAMP Signaling to Ameliorate Pulmonary Hypertension", *Circulation*, August 5, 2014, p. 496-507, DOI:10.1161/CIRCULATIONAHA.114.009751.

[0005] Despite the promising preclinical data and the identification of PDE2 as a promising drug target, no PDE2 inhibitors are currently known to be under clinical investigation due in part to the poor metabolic stability and brain penetrance of existing PDE2 compounds. There is thus a need for compounds that selectively inhibit PDE2 activity while demonstrate superior biophysical properties.

SUMMARY OF THE INVENTION

[0006] The disclosure provides novel compounds having potent and selective PDE2 inhibitory properties with improved orally availability and brain access. Therefore, in the first aspect, the disclosure provides a compound of Formula I:



Formula I

wherein

- (i) R_1 is C_{1-4} alkyl (e.g., methyl);
- 5 (ii) R_2 is selected from the group consisting of:
- H,
- OH,
- halo (e.g., chloro),
- C_{1-4} alkyl (e.g., methyl),
- 10 C_{1-4} alkoxy (e.g., methoxy or ethoxy),
- N(R_f)(R_g),
- C(O)N(R_h)(R_i),
- C(O)OR_j,
- CN,
- 15 C_{1-4} alkylthio (e.g., ethylthio),
- heteroaryl (e.g., pyrazolyl, e.g., pyrazol-1-yl),
- heteroC₃₋₇cycloalkyl (e.g., morpholinyl (e.g., morpholin-1-yl)
- or pyrrolidinyl (e.g., pyrrolidin-1-yl)), and
- aryloxy (e.g., phenoxy) wherein said aryl is optionally
- 20 substituted with one or more halo (e.g., fluoro), for example
- 4-fluorophenoxy;
- (iii) R_3 is H or C_{1-4} alkyl (e.g., methyl);
- (iv) R_a , R_b , R_c , R_d and R_e are independently H, halo (e.g., chloro or fluoro),
- O- C_{1-6} alkyl (e.g., propoxy, butoxy (e.g., n-butoxy, isobutoxy), -OCH₂-
- 25 cyclopropyl, -OCH₂-cyclobutyl or -OCH₂-cyclopentyl);

- (v) R_f and R_g are independently H, C_{1-4} alkyl (e.g., methyl) or heteroaryl (e.g., pyridyl (e.g., pyrid-2-yl));
- (vi) R_h and R_i are independently H or C_{1-4} alkyl (e.g., ethyl);
- (vii) R_j is H or C_{1-4} alkyl (e.g., ethyl);

5 in free or salt form.

[0007] The disclosure further provides the compound of Formula I as follows:

- 1.1 Formula I, wherein R_1 is C_{1-4} alkyl (e.g., methyl);
- 1.2 Formula 1.1, wherein R_1 is methyl;
- 1.3 Formula I, or any of 1.1-1.2, wherein R_2 is selected from the group


10 consisting of H; -OH; halo (e.g., chloro); C_{1-4} alkyl (e.g., methyl); C_{1-4} alkoxy (e.g., methoxy or ethoxy); $-N(R_f)(R_g)$; $-C(O)N(R_h)(R_i)$; $-C(O)OR_j$; -CN; C_{1-4} alkylthio (e.g., ethylthio); heteroaryl (e.g., pyrazolyl, e.g., pyrazol-1-yl); hetero C_{3-7} cycloalkyl (e.g., morpholinyl (e.g., morpholin-1-yl) or pyrrolidinyl (e.g., pyrrolidin-1-yl)); and

15 aryloxy (e.g., phenoxy) wherein said aryl is optionally substituted with one or more halo (e.g., fluoro), for example 4-fluorophenoxy;
- 1.4 Formula I, or any of 1.1-1.2, wherein R_2 is H;
- 1.5 Formula I, or any of 1.1-1.2, wherein R_2 is -OH;
- 1.6 Formula I, or any of 1.1-1.2, wherein R_2 is halo (e.g., chloro);
- 20 1.7 Formula I, or any of 1.1-1.2, wherein R_2 is chloro;
- 1.8 Formula I, or any of 1.1-1.2, wherein R_2 is C_{1-4} alkyl (e.g., methyl);
- 1.9 Formula I, or any of 1.1-1.2, wherein R_2 is methyl;
- 1.10 Formula I, or any of 1.1-1.2, wherein R_2 is C_{1-4} alkoxy (e.g., methoxy or ethoxy);
- 25 1.11 Formula I, or any of 1.1-1.2, wherein R_2 is methoxy;
- 1.12 Formula I, or any of 1.1-1.2, wherein R_2 is ethoxy;
- 1.13 Formula I, or any of 1.1-1.2, wherein R_2 is $N(R_f)(R_g)$;
- 1.14 Formula I or 1.13, wherein R_f and R_g are independently H, C_{1-4} alkyl (e.g., methyl) or heteroaryl (e.g., pyridyl (e.g., pyrid-2-yl));
- 30 1.15 Formula I or 1.13, wherein R_f is H and R_g is selected from H, C_{1-4} alkyl (e.g., methyl) or heteroaryl (e.g., pyridyl (e.g., pyrid-2-yl));
- 1.16 Formula I or 1.13, wherein R_f is H and R_g is pyridyl (e.g., pyrid-2-yl);
- 1.17 Formula I or 1.13, wherein R_f is H and R_g is C_{1-4} alkyl (e.g., methyl);


- 1.18 Formula I or 1.13, wherein R_f is H and R_g is methyl;
- 1.19 Formula I or 1.13, wherein R_f and R_g are both H;
- 1.20 Formula I or 1.13, wherein R_f and R_g are both C_{1-4} alkyl (e.g., methyl);
- 1.21 Formula I or 1.13, wherein R_f and R_g are both methyl;
- 5 1.22 Formula I or 1.13, wherein R_f is H and R_g is heteroaryl (e.g., pyridyl (e.g., pyrid-2-yl));
- 1.23 Formula I or 1.13, wherein R_2 is $-C(O)N(R_h)(R_i)$,
- 1.24 Formula I or 1.23, wherein R_h and R_i are independently H or C_{1-4} alkyl (e.g., ethyl);
- 10 1.25 Formula I or 1.23, wherein R_h is H and R_i is H or C_{1-4} alkyl (e.g., ethyl);
- 1.26 Formula I or 1.23, wherein R_h is H and R_i is C_{1-4} alkyl (e.g., ethyl)
- 1.27 Formula I or 1.23, wherein R_h is H and R_i is ethyl;
- 1.28 Formula I or 1.23, wherein R_h and R_i are both H;
- 15 1.29 Formula I, or any of 1.1-1.2, wherein R_2 is $-C(O)OR_j$;
- 1.30 Formula I or 1.29, wherein R_j is H or C_{1-4} alkyl (e.g., ethyl);
- 1.31 Formula I or 1.29, wherein R_j is H;
- 1.32 Formula I or 1.29, wherein R_j is C_{1-4} alkyl (e.g., ethyl);
- 1.33 Formula I or 1.29, wherein R_j is ethyl;
- 20 1.34 Formula I, or any of 1.1-1.2, wherein R_2 is $-CN$;
- 1.35 Formula I, or any of 1.1-1.2, wherein R_2 is C_{1-4} alkylthio (e.g., ethylthio);
- 1.36 Formula I, or any of 1.1-1.2, wherein R_2 is ethylthio;
- 1.37 Formula I, or any of 1.1-1.2, wherein R_2 is heteroaryl (e.g., pyrazolyl, e.g., pyrazol-1-yl);
- 25 1.38 Formula I, or any of 1.1-1.2, wherein R_2 is pyrazolyl, e.g., pyrazol-1-yl;
- 1.39 Formula I, or any of 1.1-1.2, wherein R_2 is hetero C_{3-7} cycloalkyl (e.g., morpholinyl (e.g., morpholin-1-yl) or pyrrolidinyl (e.g., pyrrolidin-1-yl));
- 30 1.40 Formula I, or any of 1.1-1.2, wherein R_2 is hetero C_{5-6} cycloalkyl;
- 1.41 Formula I, or any of 1.1-1.2, wherein R_2 is morpholinyl (e.g., morpholin-1-yl);

- 1.42 Formula I, or any of 1.1-1.2, wherein R₂ is pyrrolidinyl (e.g., pyrrolidin-1-yl);
- 1.43 Formula I, or any of 1.1-1.2, wherein R₂ is aryloxy (e.g., phenoxy) wherein said aryl is optionally substituted with one or more halo (e.g., fluoro), for example 4-fluorophenoxy;
- 1.44 Formula I, or any of 1.1-1.2, wherein R₂ is phenoxy wherein said phenyl is optionally substituted with one or more halo (e.g., fluoro), for example 4-fluorophenoxy;
- 1.45 Formula I, or any of 1.1-1.2, wherein R₂ is 4-fluorophenoxy;
- 1.46 Formula I or any of 1.1-1.45, wherein R₃ is H or C₁₋₄alkyl (e.g., methyl);
- 1.47 Formula I or any of 1.1-1.45, wherein R₃ is H;
- 1.48 Formula I or any of 1.1-1.45, wherein R₃ is C₁₋₄alkyl (e.g., methyl);
- 1.49 Formula I or any of 1.1-1.45, wherein R₃ is methyl;
- 1.50 Formula I or any of 1.1-1.49, wherein R_a, R_b, R_c, R_d and R_e are independently H, halo (e.g., chloro or fluoro), -O-C₁₋₆alkyl (e.g., propoxy, butoxy (e.g., n-butoxy, isobutoxy), -OCH₂-cyclopropyl, -OCH₂-cyclobutyl or -OCH₂-cyclopentyl);
- 1.51 Formula I or any of 1.1-1.50, wherein R_a, R_b, R_c, R_d and R_e are independently H;
- 1.52 Formula I or any of 1.1-1.51, wherein R_a, R_b, R_c, R_d and R_e are independently halo (e.g., chloro or fluoro);
- 1.53 Formula I or any of 1.1-1.51, wherein R_a, R_b, R_c, R_d and R_e are independently chloro or fluoro;
- 1.54 Formula I or any of 1.1-1.53, wherein R_a, R_b, R_c, R_d and R_e are independently -O-C₁₋₆alkyl (e.g., propoxy, butoxy (e.g., n-butoxy, isobutoxy), -OCH₂-cyclopropyl, -OCH₂-cyclobutyl or -OCH₂-cyclopentyl);
- 1.55 Formula I or any of 1.1-1.53, wherein R_a, R_b, R_c, R_d and R_e are independently -O-C₃₋₆alkyl;
- 1.56 Formula I or any of 1.1-1.55, wherein R_b, R_c and R_e are all H;
- 1.57 Formula I or any of 1.1-1.56, wherein R_b, R_c and R_e are all H; and R_a and R_d are independently selected from H, halo (e.g., chloro or fluoro),


- O-C₁₋₆alkyl (e.g., propoxy, butoxy (e.g., n-butoxy, isobutoxy), -OCH₂-cyclopropyl, -OCH₂-cyclobutyl or -OCH₂-cyclopentyl);
- 1.58 Formula I or any of 1.1-1.56, wherein R_b, R_c and R_e are all H; R_a is halo (e.g., chloro or fluoro); and R_d is H, halo (e.g., chloro or fluoro) or -O-C₁₋₆alkyl (e.g., propoxy, butoxy (e.g., n-butoxy, isobutoxy), -OCH₂-cyclopropyl, -OCH₂-cyclobutyl or -OCH₂-cyclopentyl);
- 1.59 Formula I or any of 1.1-1.56, wherein R_b, R_c and R_e are all H; R_a is halo (e.g., chloro or fluoro); and R_d is H;
- 1.60 Formula I or any of 1.1-1.56, wherein R_b, R_c and R_e are all H; and R_a and R_d are both halo (e.g., chloro or fluoro);
- 1.61 Formula I or any of 1.1-1.56, wherein R_b, R_c and R_e are all H; R_a and R_d are both chloro;
- 1.62 Formula I or any of 1.1-1.56, wherein R_b, R_c and R_e are all H; R_a is halo (e.g., chloro or fluoro); and R_d is -O-C₁₋₆alkyl (e.g., propoxy, butoxy (e.g., n-butoxy, isobutoxy), -OCH₂-cyclopropyl, -OCH₂-cyclobutyl or -OCH₂-cyclopentyl);
- 1.63 Formula I or any of 1.1-1.56, wherein R_b, R_c and R_e are all H; R_a is halo (e.g., chloro or fluoro); and R_d is -O-C₃₋₆alkyl (e.g., propoxy, butoxy (e.g., n-butoxy, isobutoxy), -OCH₂-cyclopropyl, -OCH₂-cyclobutyl or -OCH₂-cyclopentyl);
- 1.64 Formula I or any of 1.1-1.56, wherein R_b, R_c and R_e are all H; R_a is chloro; and R_d is butoxy (e.g., n-butoxy, isobutoxy);
- 1.65 Formula I or any of 1.1-1.56, wherein R_b, R_c and R_e are all H; R_a is chloro; and R_d is n-butoxy;
- 1.66 Formula I or any of 1.1-1.56, wherein R_b, R_c and R_e are all H; R_a is halo (e.g., chloro or fluoro); and R_d is -O-C₁₋₆alkyl (e.g., propoxy, butoxy (e.g., n-butoxy, isobutoxy), -OCH₂-cyclopropyl, -OCH₂-cyclobutyl or -OCH₂-cyclopentyl);
- 1.67 Formula I or any of 1.1-1.56, wherein R_a, R_b, R_c and R_e are all H and R_d is -O-C₁₋₆alkyl;
- 1.68 any of the preceding formulae, wherein the compound is Formula I(i):



1.69 any of the preceding formulae, wherein the compound is Formula I(ii):



1.70 any of the preceding formulae, wherein the compound is Formula I(iii):



1.71 any of the preceding formulae, wherein the compound is selected from a group consisting of:

1-(5-Butoxy-2-fluorophenyl)-8-(4-fluorophenoxy)-3-methyl-
1*H*-pyrazolo[4,3-*c*][1,5]naphthyridin-4(5*H*)-one;


- 1-(5-Butoxy-2-fluorophenyl)-8-(dimethylamino)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
- 1-(5-Butoxy-2-fluorophenyl)-3-methyl-8-(pyrrolidin-1-yl)-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
- 5 1-(5-Butoxy-2-fluorophenyl)-3-methyl-8-(1H-pyrazol-1-yl)-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
- 1-(5-Butoxy-2-fluorophenyl)-3-methyl-8-(pyridin-2-ylamino)-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
- 1-(5-Butoxy-2-fluorophenyl)-8-(ethylthio)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
- 10 1-(5-Butoxy-2-fluorophenyl)-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carbonitrile;
- 1-(5-Butoxy-2-fluorophenyl)-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxylic acid;
- 15 Ethyl 1-(5-butoxy-2-fluorophenyl)-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxylate;
- 1-(5-Butoxy-2-fluorophenyl)-N-ethyl-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxamide;
- 20 1-(5-Butoxy-2-fluorophenyl)-3-methyl-4-oxo-3a,4-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxamide;
- 8-Chloro-1-(2-chloro-5-(cyclopropylmethoxy)phenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
- 25 1-(2,5-Dichlorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
- 1-(2-Chlorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
- 1-(2-Chlorophenyl)-3,5-dimethyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
- 30 1-(2,5-Dichlorophenyl)-3,5-dimethyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;

- 1-(5-Butoxy-2-chlorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
 1-(5-Butoxy-2-fluorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
 5 8-Chloro-1-(2,5-dichlorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
 1-(5-Butoxy-2-chlorophenyl)-8-chloro-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
 1-(5-Butoxy-2-chlorophenyl)-8-methoxy-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one; and
 10 1-(2-Chloro-5-(cyclobutylmethoxy)phenyl)-8-methoxy-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;

- 1.72 any of the preceding formulae wherein the compounds inhibit phosphodiesterase-mediated (e.g., PDE2-mediated) hydrolysis of cGMP, e.g., with an IC_{50} of less than $2\mu M$, more preferably less than or equal to 250 nM, more preferably less than or equal to 10 nM in a PDE assay, for example, as described in Example 23,

in free or salt form.

- [0008] In a particular embodiment, the disclosure provides a compound of
 20 Formula I(i):



Formula I(i)

wherein

- (i) R₁ is C₁₋₄alkyl (e.g., methyl);
 25 (ii) R₂ is C₁₋₄alkoxy (e.g., methoxy or ethoxy);
 (iii) R₃ is H;

- (iv) R_b , R_c and R_e are H; R_a is halo and R_d is $-O-C_{1-6}$ alkyl (e.g., propoxy, butoxy (e.g., n-butoxy, isobutoxy), $-OCH_2$ -cyclopropyl, $-OCH_2$ -cyclobutyl or $-OCH_2$ -cyclopentyl);

in free or salt form.

- 5 **[0009]** In a particular embodiment, the disclosure provides a compound of Formula I(i) wherein

- (i) R_1 is C_{1-4} alkyl (e.g., methyl);
(ii) R_2 is C_{1-4} alkoxy (e.g., methoxy or ethoxy);
(iii) R_3 is H;

- 10 (iv) R_b , R_c and R_e are H; R_a is halo and R_d is $-OCH_2$ -cyclobutyl;
in free or salt form.

- [0010]** In a second aspect, the disclosure provides a pharmaceutical composition comprising a Compound of the Disclosure, i.e., Compounds of Formula I, I(i), I(ii) or I(iii), or any of formulae 1.1-1.72, in free or pharmaceutically acceptable salt form, in combination or association with a pharmaceutically acceptable diluents or carrier.

- [0011]** The disclosure also provides methods of using the Compounds of the Disclosure for treatment of PDE2-mediated disorders, e.g., disorders as set forth below (especially treatment of anxiety, depression, autism spectrum disorder (ASD), schizophrenia, cognitive impairment). This list is not intended to be exhaustive and may include other diseases and disorders as set forth below.

- [0012]** Therefore, in a third aspect, the disclosure provides a method for the treatment of a PDE2-mediated disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a Compound of the Disclosure disclosed herein, i.e., Compounds of Formula I, I(i), I(ii) or I(iii), or any of formulae 1.1-1.72, in free or pharmaceutically acceptable salt form, or a pharmaceutical composition disclosed herein.

- [0013]** In a further embodiment of the third aspect, the disclosure provides a method for the treatment of the following disorders:

- 30 neurological disorders (such as migraine; epilepsy; Alzheimer's disease; Parkinson's disease; brain injury; stroke; cerebrovascular diseases (including cerebral arteriosclerosis, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, and brain hypoxia-ischemia); spinal muscular atrophy; lateral sclerosis; multiple sclerosis;

- cognitive disorders (including amnesia, senile dementia, HIV associated dementia, Alzheimer's associated dementia, Huntington's associated dementia, Lewy body dementia, vascular dementia, drug related dementia, delirium, and mild cognitive impairment); and cognitive dysfunction associated with Parkinson's disease
- 5 and depression;
- mental deficiency (including Down syndrome and fragile X syndrome);
- sleep disorders (including hypersomnia, circadian rhythm sleep disorder, insomnia, parasomnia, and sleep deprivation);
- psychiatric disorders (such as anxiety (including acute stress disorder,
- 10 generalized anxiety disorder, social anxiety disorder, panic disorder, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder, specific phobia, social phobia, chronic anxiety disorder and obsessive compulsive disorder,);
- factitious disorder (including acute hallucinatory mania);
- impulse control disorders (including pathological gambling, pathological fire-
- 15 setting, pathological stealing and intermittent explosive disorder);
- mood disorders (including bipolar I disorder, bipolar II disorder, mania, mixed affective state, major depression, chronic depression, seasonal depression, psychotic depression and postpartum depression);
- psychomotor disorders (extrapyramidal and movement disorders, e.g.,
- 20 Parkinsonism, Lewy body disease, tremor, drug-induced tremor, drug-induced tardive dyskinesia, L-dopa-induced dyskinesia and restless leg syndrome);
- psychotic disorders (including schizophrenia (e.g., continuous or episodic, paranoid, hebephrenic, catatonic, undifferentiated and residual schizophrenic disorders), schizoaffective disorder, schizophreniform, and delusional disorder);
- 25 drug dependence (including narcotic dependence, alcoholism, amphetamine dependence, cocaine addiction, nicotine dependence, and drug withdrawal syndrome);
- eating disorders (including anorexia, bulimia, binge eating disorder, hyperphagia, and pagophagia);
- pediatric psychiatric disorders (including attention deficit disorder, attention
- 30 deficit/hyperactive disorder, conduct disorder (e.g., tic disorders such as transient, chronic, motor or vocal tic disorders), autism and autism spectrum disorder (ASD));
- mental and behavioral disorders due to psychoactive substance use;

cardiovascular disorder (e.g., pulmonary hypertension and pulmonary arterial hypertension); and

pain (e.g., bone and joint pain (osteoarthritis), repetitive motion pain, dental pain, cancer pain, myofascial pain (muscular injury, fibromyalgia), perioperative pain (general surgery, gynecological), chronic pain and neuropathic pain),
5 in a subject, preferably a mammal, preferably a human, comprising administering to said subject a therapeutically effective amount of a Compound of the Disclosure disclosed herein, i.e., Compounds of Formula I, I(i), I(ii) or I(iii), or any of formulae 1.1-1.72, in free or pharmaceutically acceptable salt form, or a pharmaceutical
10 composition disclosed herein.

[0014] In one embodiment, the disease or disorder is selected from a group consisting of anxiety, depression, autism spectrum disorder and schizophrenia, for example anxiety and/or depression in autistic and/or schizophrenic patients.. In another embodiment, the disease or disorder is cognitive impairment associated with
15 schizophrenia or dementia.

[0015] In the fourth aspect, the disclosure provides a Compound of the Disclosure disclosed herein, i.e., Compounds of Formula I, I(i), I(ii) or I(iii), or any of formulae 1.1-1.72, in free or pharmaceutically acceptable salt form (for use in the manufacture of a medicament) for the treatment of a PDE2-mediated disorder as
20 disclosed herein.

[0016] In the fifth aspect, the disclosure provides a pharmaceutical composition comprising a Compound of the Disclosure disclosed herein, i.e., Compounds of Formula I, I(i), I(ii) or I(iii), or any of formulae 1.1-1.72, in free or pharmaceutically acceptable salt form, in combination or association with a
25 pharmaceutically acceptable diluents or carrier, for use in the treatment of a PDE2-mediated disorder as disclosed herein.

DETAILED DESCRIPTION OF THE INVENTION

[0017] If not otherwise specified or clear from context, the following terms
30 herein have the following meanings:

- (a) “Alkyl” as used herein is a saturated or unsaturated hydrocarbon moiety, preferably saturated, preferably having one to six carbon atoms, preferably having one to four carbon atoms, which may be

linear or branched, and may be optionally mono-, di- or tri-substituted, e.g., with halogen (e.g., chloro or fluoro), hydroxy, or carboxy.

- 5 (b) “Aryl” as used herein is a mono or bicyclic aromatic hydrocarbon, preferably phenyl, optionally substituted, e.g., with alkyl (e.g., methyl), halogen (e.g., chloro or fluoro), haloalkyl (e.g., trifluoromethyl) or hydroxy.
- 10 (c) “Heteroaryl” as used herein is an aromatic moiety wherein one or more of the atoms making up the aromatic ring is sulfur or nitrogen rather than carbon, e.g., pyridyl or thiadiazolyl, which may be optionally substituted, e.g., with alkyl, halogen, haloalkyl or hydroxy.

[0018] Compounds of the Disclosure, e.g., Compounds of Formula I, I(i), I(ii) or I(iii), e.g., any of formulae 1.1-1.72, may exist in free or salt form, e.g., as acid addition salts. In this specification unless otherwise indicated, language such as

15 “Compounds of the Disclosure” is to be understood as embracing the compounds in any form, for example free or acid addition salt form, or where the compounds contain acidic substituents, in base addition salt form. The Compounds of the Disclosure are intended for use as pharmaceuticals, therefore pharmaceutically acceptable salts are preferred. Salts which are unsuitable for pharmaceutical uses may

20 be useful, for example, for the isolation or purification of free Compounds of the Disclosure or their pharmaceutically acceptable salts, are therefore also included. Compounds of the Disclosure may in some cases also exist in prodrug form. A prodrug form is compound which converts in the body to a Compound of the Disclosure. For example when the Compounds of the Disclosure contain hydroxy or

25 carboxy substituents, these substituents may form physiologically hydrolysable and acceptable esters. As used herein, “physiologically hydrolysable and acceptable ester” means esters of Compounds of the Disclosure which are hydrolysable under physiological conditions to yield acids (in the case of Compounds of the Disclosure which have hydroxy substituents) or alcohols (in the case of Compounds of the

30 Disclosure which have carboxy substituents) which are themselves physiologically tolerable at doses to be administered. Therefore, wherein the Compound of the Disclosure contains a hydroxy group, for example, Compound-OH, the acyl ester prodrug of such compound, i.e., Compound-O-C(O)-C₁₋₄alkyl, can hydrolyze in the

body to form physiologically hydrolysable alcohol (Compound-OH) on the one hand and acid on the other (e.g., HOC(O)-C₁₋₄alkyl). Alternatively, wherein the Compound of the Disclosure contains a carboxylic acid, for example, Compound-C(O)OH, the acid ester prodrug of such compound, Compound-C(O)O-C₁₋₄alkyl can hydrolyze to
5 form Compound-C(O)OH and HO-C₁₋₄alkyl. As will be appreciated, the term thus embraces conventional pharmaceutical prodrug forms.

[0019] The Compounds of the Disclosure herein include their enantiomers, diastereoisomers and racemates, as well as their polymorphs, hydrates, solvates and complexes. Some individual compounds within the scope of this invention may
10 contain double bonds. Representations of double bonds in this invention are meant to include both the E and the Z isomer of the double bond. In addition, some compounds within the scope of this invention may contain one or more asymmetric centers. This invention includes the use of any of the optically pure stereoisomers as well as any combination of stereoisomers.

15 **[0020]** It is also intended that the Compounds of the Disclosure encompass their stable and unstable isotopes. Stable isotopes are nonradioactive isotopes which contain one additional neutron compared to the abundant nuclides of the same species (i.e., element). It is expected that the activity of compounds comprising such isotopes would be retained, and such compound would also have utility for measuring
20 pharmacokinetics of the non-isotopic analogs. For example, the hydrogen atom at a certain position on the Compounds of the Disclosure may be replaced with deuterium (a stable isotope which is non-radioactive). Examples of known stable isotopes include, but not limited to, deuterium, ¹³C, ¹⁵N, ¹⁸O. Alternatively, unstable isotopes, which are radioactive isotopes which contain additional neutrons compared
25 to the abundant nuclides of the same species (i.e., element), e.g., ¹²³I, ¹³¹I, ¹²⁵I, ¹¹C, ¹⁸F, may replace the corresponding abundant species of I, C and F. Another example of useful isotope of the compound of the invention is the ¹¹C isotope. These radio isotopes are useful for radio-imaging and/or pharmacokinetic studies of the compounds of the invention. Isotopically-labeled compounds of Formula I may
30 generally be prepared by carrying out by substituting an isotopically-labeled reagent for a non-isotopically-labeled reagent.

[0010] The phrase “Compounds of the Disclosure” or “PDE 2 inhibitors of the Disclosure” encompasses any and all of the compounds disclosed herewith, e.g., a

Compound of Formula I, I(i), I(ii), I(iii) or any of 1.1-1.72 as hereinbefore described, in free or salt form.

[0011] The words "treatment" and "treating" are to be understood accordingly as embracing treatment or amelioration of symptoms of the disease as well as
5 treatment of the cause of the disease. In one embodiment, the invention provides a method for the treatment of the disease or disorder disclosed herein. In another embodiment, the invention provides a method for the prophylaxis of a disease or disorder as disclosed herein.

[0012] For methods of treatment, the word "effective amount" is intended to
10 encompass a therapeutically effective amount to treat a specific disease or disorder.

[0013] The term "pulmonary hypertension" is intended to encompass pulmonary arterial hypertension.

[0014] The term "subject" includes human or non-human (i.e., animal). In particular embodiment, the invention encompasses both human and nonhuman. In
15 another embodiment, the invention encompasses nonhuman. In other embodiment, the term encompasses human.

[0015] The term "comprising" as used in this disclosure is intended to be open-ended and does not exclude additional, unrecited elements or method steps.

[0016] The term "cognitive disorders" refers to any disorder comprising a
20 symptom of cognitive deficiency (i.e., subnormal or suboptimal functioning in one or more cognitive aspects such as memory, intellect, learning, logic, attention or executive function (working memory) in an individual compared to other individuals within the same general age population). Therefore, cognitive disorders include but are not limited to amnesia, senile dementia, HIV associated dementia, Alzheimer's
25 associated dementia, Huntington's associated dementia, Lewy body dementia, vascular dementia, drug related dementia, delirium, and mild cognitive impairment. Cognitive disorders can also be a disorder primarily but not exclusively related to psychosis (schizophrenia), mood disorders, bipolar disorders, stroke, frontotemporal dementia, progressive supranuclear palsy, cerebral trauma and drug abuse, Asperger's
30 syndrome and age-associated memory impairment.

[0017] Compounds of the Disclosure, e.g., Compounds of Formula I, I(i), I(ii) or I(iii), e.g., any of formulae 1.1-1.72, as hereinbefore described, in free or

pharmaceutically acceptable salt form may be used as a sole therapeutic agent, but may also be used in combination or for co-administration with other active agents.

[0018] Dosages employed in practicing the present invention will of course vary depending, e.g. on the particular disease or condition to be treated, the particular
5 Compound of the Disclosure used, the mode of administration, and the therapy desired. Compounds of the Disclosure may be administered by any suitable route, including orally, parenterally, transdermally, or by inhalation, but are preferably administered orally. In general, satisfactory results, e.g. for the treatment of diseases as hereinbefore set forth are indicated to be obtained on oral administration at dosages
10 of the order from about 0.01 to 2.0 mg/kg. In larger mammals, for example humans, an indicated daily dosage for oral administration will accordingly be in the range of from about 0.75 to 150 mg, conveniently administered once, or in divided doses 2 to 4 times, daily or in sustained release form. Unit dosage forms for oral administration thus for example may comprise from about 0.2 to 75 or 150 mg, e.g. from about 0.2
15 or 2.0 to 50, 75 or 100 mg of a Compound of the Disclosure, together with a pharmaceutically acceptable diluent or carrier therefor.


[0019] Pharmaceutical compositions comprising Compounds of the Disclosure may be prepared using conventional diluents or excipients and techniques known in the galenic art. The pharmaceutically acceptable carrier may comprise any
20 conventional pharmaceutical carrier or excipient. Suitable pharmaceutical carriers include inert diluents or fillers, water and various organic solvents (such as hydrates and solvates). The pharmaceutical compositions may, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus for oral administration, tablets containing various excipients, such as citric acid, may be
25 employed together with various disintegrants such as starch, alginic acid and certain complex silicates and with binding agents such as sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed in soft and hard filled gelatin capsules. Non-limiting examples
30 of materials, therefore, include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration the active compound therein may be combined with various sweetening or flavoring agents, coloring matters or dyes and, if desired, emulsifying

agents or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin, or combinations thereof. The pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulation, solution or suspension, for parenteral injection
5 as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.

[0020] The compounds of the Disclosure herein and their pharmaceutically acceptable salts may be made using the methods as described and exemplified herein and by methods similar thereto and by methods known in the chemical art. Such
10 methods include, but not limited to, those described below. If not commercially available, starting materials for these processes may be made by procedures, which are selected from the chemical art using techniques which are similar or analogous to the synthesis of known compounds. All references cited herein are hereby incorporated by reference in their entirety.

Example 1

1-(5-Butoxy-2-fluorophenyl)-8-(4-fluorophenoxy)-3-methyl-1*H*-pyrazolo[4,3-*c*][1,5]naphthyridin-4(5*H*)-one



(a) 5-Butoxy-2-fluorobenzenamine

[0021] A mixture of 4-fluoro-3-nitrophenol (1) (2.81 g, 17.9 mmol), 1-bromobutane (3.43 g, 25.0 mmol) and cesium carbonate (11.6 g, 35.7 mmol) in anhydrous DMF (15 mL) is stirred at room temperature for 18 h. After the solvent is
25 removed under reduced pressure, the residue is treated with water (400 mL) and extracted with methylene (3 × 50 mL). The combined organic phase is evaporated to dryness to give 4-butoxy-1-fluoro-2-nitrobenzene as an orange oil. To a solution of the crude 4-butoxy-1-fluoro-2-nitrobenzene in EtOH (10 mL) is slowly added concentrated HCl (10 mL). The mixture is stirred at room temperature for 5 min, and
30 then tin(II) chloride (8.40 g, 44.3 mmol) is added. After stirring at room temperature

for 16 h, the reaction mixture is treated with water (500 mL) and extracted with methylene (4 × 50 mL). The combined organic phase is washed with brine (40mL), and then evaporated to dryness under reduced pressure. The obtained crude product is further purified with a neutral alumina oxide column using a gradient of 0 – 100% ethyl acetate in hexane as eluent to give 5-butoxy-2-fluorobenzenamine an oil (2.42 g, 74% yield). MS (ESI) m/z 184.1 [M+H]⁺.

(b) (5-Butoxy-2-fluorophenyl)hydrazine

[0022] A solution of sodium nitrite (1.04 g, 15.1 mmol) in water (5 mL) is added dropwise to a suspension of 5-butoxy-2-fluorobenzenamine (2.30 g, 12.6 mmol) in concentrated hydrochloric acid (12 mL) at 0 °C. After the completion of the addition, the reaction mixture is stirred at 0 °C for 30 min, and then a solution of tin (II) chloride dihydrate (6.86 g, 30.4 mmol) in concentrated hydrochloric acid (3mL) is added. The reaction mixture is stirred at room temperature overnight, and then filtered. The filter cake is washed with 6 N HCl (3 × 4 mL) and hexane (3 × 5 mL) successively, and then dried under vacuum to give 3.18 g of the crude product, which is used directly in the next step without further purification. MS (ESI) m/z 199.1 [M+H]⁺.

(c) 8-Bromo/Chloro-1-(5-butoxy-2-fluorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one


[0023] To a suspension of (4-butoxy-2-fluorophenyl)hydrazine (860 mg, 4.34 mmol) and 3-acetyl-6-bromo-4-hydroxy-1,5-naphthyridin-2(1H)-one (500 mg, 1.77 mmol) in dioxane (4 mL) is added concentrated HCl (0.1 mL). The reaction mixture in a sealed tube is stirred at room temperature for 5 min and then heated in a microwave reactor at 160 °C for 5 h. After cooled to room temperature, the reaction mixture is treated with water (200 mL) and then extracted with CH₂Cl₂/MeOH (10/1) (4 × 50 mL). The combined organic phase is evaporated to dryness. The obtained residue is purified by silica-gel column chromatography using a gradient of 0 – 100% ethyl acetate in hexane as eluent to give 580 mg of product, which contains 22% of 8-chloro-1-(5-butoxy-2-fluorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one (MS (ESI) m/z 401.1 [M+H]⁺) and 68% 8-bromo-1-(5-butoxy-2-fluorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one (MS (ESI) m/z 445.1 [M+H]⁺). The two compounds co-eluted on the column and are used directly in the next step without further separation.

**(d) 1-(5-Butoxy-2-fluorophenyl)-8-(4-fluorophenoxy)-3-methyl-1H-pyrazolo[4,3-
c][1,5]naphthyridin-4(5H)-one**

[0024] A suspension of 8-bromo/chloro-1-(5-butoxy-2-fluorophenyl)-3-methyl-1H-pyrazolo[4,3-
c][1,5]naphthyridin-4(5H)-one (41.0 mg), 4-fluorophenol
5 (112 mg, 1.00 mmol) and cesium carbonate (97 mg, 0.30 mmol) in dioxane (0.6 mL)
in a sealed microwave vial is heated in a microwave reactor at 160 °C for 5 h. After
cooled to room temperature, the reaction mixture is treated with water (100 mL) and
extracted with CH₂Cl₂ (4 × 25 mL). The combined organic phase is evaporated to
dryness. The obtained residue is purified with a semi-preparative HPLC system using
10 a gradient of 0 – 70% acetonitrile in water containing 0.1% formic acid over 16 min
to give 17 mg of 1-(5-butoxy-2-fluorophenyl)-8-(4-fluorophenoxy)-3-methyl-1H-
pyrazolo[4,3-*c*][1,5]naphthyridin-4(5H)-one as an off-white solid. ¹H NMR (500
MHz, Chloroform-*d*) δ 11.24 (s, 1H), 7.81 (d, *J* = 8.9 Hz, 1H), 7.13 (d, *J* = 8.8 Hz,
1H), 6.88 (dd, *J* = 6.0, 3.1 Hz, 1H), 6.85 – 6.78 (m, 4H), 6.76 – 6.70 (m, 1H), 6.62
15 (dd, *J* = 9.2, 9.2 Hz, 1H), 4.03 – 3.78 (m, 2H), 2.79 (s, 3H), 1.81 – 1.74 (m, 2H), 1.58
– 1.45 (m, 2H), 1.00 (t, *J* = 7.4 Hz, 3H). MS (ESI) *m/z* 477.2 [M+H]⁺.

Example 2


**1-(5-Butoxy-2-fluorophenyl)-8-(dimethylamino)-3-methyl-1H-pyrazolo[4,3-
c][1,5]naphthyridin-4(5H)-one**



[0025] The title compound is prepared in an analogous fashion following the
procedure described in the synthesis of Example 1 wherein 40% dimethylamine
solution is added in step (d) instead of 4-fluorophenol. ¹H NMR (500 MHz,
25 Chloroform-*d*) δ 10.82 (s, 1H), 7.56 (d, *J* = 9.1 Hz, 1H), 7.15 – 7.08 (m, 2H), 6.99 –
6.92 (m, 1H), 6.80 (d, *J* = 9.0 Hz, 1H), 3.97 (t, *J* = 6.5 Hz, 2H), 2.81 (s, 3H), 2.77 (s,
6H), 1.81 – 1.71 (m, 2H), 1.53 – 1.42 (m, 2H), 0.96 (t, *J* = 7.4 Hz, 3H). MS (ESI) *m/z*
410.2 [M+H]⁺.

30 Example 3


1-(5-Butoxy-2-fluorophenyl)-3-methyl-8-(pyrrolidin-1-yl)-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one



[0026] The title compound is prepared in an analogous fashion following the procedure described in the synthesis of Example 1 wherein pyrrolidine is added in step (d) instead of 4-fluorophenol. ¹H NMR (500 MHz, Chloroform-*d*) δ 10.28 (s, 1H), 7.47 (d, *J* = 9.0 Hz, 1H), 7.15 – 7.08 (m, 2H), 7.00 – 6.92 (m, 1H), 6.55 (d, *J* = 9.0 Hz, 1H), 3.97 (t, *J* = 6.5 Hz, 2H), 3.16 – 3.01 (m, 4H), 2.80 (s, 3H), 1.95 – 1.84 (m, 4H), 1.80 – 1.71 (m, 2H), 1.53 – 1.43 (m, 2H), 0.96 (t, *J* = 7.4, 7.4 Hz, 3H). MS (ESI) *m/z* 436.2 [M+H]⁺.

Example 4


1-(5-Butoxy-2-fluorophenyl)-3-methyl-8-(1H-pyrazol-1-yl)-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one



[0027] The title compound is prepared in an analogous fashion following the procedure described in the synthesis of Example 1 wherein 1H-pyrazole is added in step (d) instead of 4-fluorophenol. ¹H NMR (500 MHz, Chloroform-*d*) δ 10.83 (s, 1H), 8.15 (d, *J* = 8.9 Hz, 1H), 7.83 (d, *J* = 8.9 Hz, 1H), 7.67 (dd, *J* = 1.7, 0.8 Hz, 1H), 7.59 (dd, *J* = 2.6, 0.8 Hz, 1H), 7.25 – 7.16 (m, 2H), 7.14 – 7.08 (m, 1H), 6.33 (dd, *J* = 2.6, 1.6 Hz, 1H), 4.00 (t, *J* = 6.5 Hz, 2H), 2.84 (s, 3H), 1.82 – 1.72 (m, 2H), 1.53 – 1.43 (m, 2H), 0.96 (t, *J* = 7.4 Hz, 3H). MS (ESI) *m/z* 433.2 [M+H]⁺.

Example 5


1-(5-Butoxy-2-fluorophenyl)-3-methyl-8-(pyridin-2-ylamino)-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one



[0028] A suspension of the crude 8-bromo/chloro-1-(5-butoxy-2-fluorophenyl)-3-methyl-1*H*-pyrazolo[4,3-*c*][1,5]naphthyridin-4(5*H*)-one synthesized in step c of Example 1 (41.0 mg), pyridin-2-amine (160 mg, 1.7 mmol), Pd₂(dba)₃ (8 mg), Xantphos (10 mg) and cesium carbonate (130 mg, 0.40 mmol) in dioxane (0.6 mL) is heated in at 100 °C for 60 h. After cooled to room temperature, the reaction mixture is treated with DMF (5 mL) and then filtered. The filtrate is isolated with a semi-preparative HPLC system using a gradient of 0 – 30% acetonitrile in water containing 0.1% formic acid over 16 min to give 11 mg of 1-(5-butoxy-2-fluorophenyl)-3-methyl-8-(pyridin-2-ylamino)-1*H*-pyrazolo[4,3-*c*][1,5]naphthyridin-4(5*H*)-one as an off-white solid. ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.43 (s, 1H), 9.67 (s, 1H), 8.16 – 8.09 (m, 1H), 7.68 (d, *J* = 9.0 Hz, 1H), 7.38 – 7.32 (m, 1H), 7.32 – 7.27 (m, 2H), 7.19 – 7.10 (m, 2H), 6.98 – 6.91 (m, 1H), 6.83 – 6.76 (m, 1H), 3.99 (t, *J* = 6.4 Hz, 2H), 2.60 (s, 3H), 1.71 – 1.60 (m, 2H), 1.45 – 1.31 (m, 2H), 0.87 (t, *J* = 7.4 Hz, 3H). MS (ESI) *m/z* 459.2 [M+H]⁺.

Example 6

1-(5-Butoxy-2-fluorophenyl)-8-(ethylthio)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one




[0029] The title compound is prepared in an analogous fashion following the procedure described in the synthesis of Example 1 wherein ethanethiol is added in step (d) instead of 4-fluorophenol. ¹H NMR (500 MHz, Chloroform-*d*) δ 11.00 (s, 1H), 7.56 (d, *J* = 8.7 Hz, 1H), 7.24 (d, *J* = 8.7 Hz, 1H), 7.18 – 7.09 (m, 2H), 7.03 –

6.98 (m, 1H), 3.97 (t, $J = 6.4$ Hz, 2H), 2.81 (s, 3H), 2.51 (q, $J = 7.4$ Hz, 2H), 1.81 – 1.73 (m, 2H), 1.53 – 1.44 (m, 2H), 1.01 (t, $J = 7.4$ Hz, 3H), 0.97 (t, $J = 7.4$ Hz, 3H). MS (ESI) m/z 427.2 $[M+H]^+$.

5 Example 7


1-(5-Butoxy-2-fluorophenyl)-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-*c*][1,5]naphthyridine-8-carbonitrile



- [0030]** A suspension of the crude 8-bromo/chloro-1-(5-butoxy-2-fluorophenyl)-3-methyl-1H-pyrazolo[4,3-*c*][1,5]naphthyridin-4(5H)-one prepared in step c of Example 1 (140 mg) and copper(I) cyanide (50 mg, 0.56 mmol) in pyridine (1.5 mL) in a seal microwave vial is heated in a microwave reactor at 180 °C for 5 h. After cooled to room temperature, the solvent is removed under reduced pressure. The residue is treated with ethyl acetate (15 mL), and then filtered. The filtrate is washed with water three times (3×5 mL), and then evaporated to dryness. The obtained crude product is purified by silica gel column chromatography to give 71 mg of 1-(5-butoxy-2-fluorophenyl)-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-*c*][1,5]naphthyridine-8-carbonitrile as an off white solid. ^1H NMR (500 MHz, Chloroform-*d*) δ 11.23 (s, 1H), 7.80 (d, $J = 8.5$ Hz, 1H), 7.73 (d, $J = 8.2$ Hz, 1H), 7.23 – 7.15 (m, 1H), 7.13 – 7.08 (m, 1H), 7.08 – 7.01 (m, 1H), 4.00 (t, $J = 6.5$ Hz, 2H), 2.82 (s, 3H), 1.84 – 1.74 (m, 2H), 1.53 – 1.47 (m, 2H), 0.98 (t, $J = 7.4$ Hz, 3H). MS (ESI) m/z 392.1 $[M+H]^+$.

Example 8


- 1-(5-Butoxy-2-fluorophenyl)-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-*c*][1,5]naphthyridine-8-carboxylic acid



[0031] To a suspension of 1-(5-butoxy-2-fluorophenyl)-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carbonitrile (56 mg, 0.14 mmol) in dioxane (1.0 mL) is added concentrated hydrochloric acid (0.15 mL). The reaction mixture is stirred at 100 °C for 24 h. After the solvents are removed under reduced pressure, the residue is further dried under vacuum to afford 1-(5-butoxy-2-fluorophenyl)-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxylic acid (45 mg, 77% yield) as an off white solid. ¹H NMR (500 MHz, Chloroform-*d*) δ 10.87 (s, 1H), 9.49 (s, 1H), 8.30 (d, *J* = 8.1 Hz, 1H), 7.90 (d, *J* = 8.4 Hz, 1H), 7.30 – 7.23 (m, 1H), 7.19 – 7.15 (m, 1H), 7.14 – 7.08 (m, 1H), 4.12 – 3.92 (m, 2H), 2.84 (s, 3H), 1.86 – 1.74 (m, 2H), 1.53 – 1.45 (m, 2H), 0.98 (t, *J* = 7.4, 7.4 Hz, 3H). MS (ESI) *m/z* 411.1 [M+H]⁺.

Example 9

Ethyl 1-(5-butoxy-2-fluorophenyl)-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxylate




[0032] A mixture of 1-(5-butoxy-2-fluorophenyl)-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxylic acid (20 mg, 0.049 mmol) and concentrated sulfuric acid (10 μ L) in ethanol (0.60 mL) in a sealed microwave vial is heated in a microwave reactor at 120 °C for 1 h. After cooled to room temperature, the reaction mixture is concentrated under reduced pressure. The obtained residue is purified with a semi-preparative HPLC to give ethyl 1-(5-butoxy-2-fluorophenyl)-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxylate (17 mg, 77% yield) as an off white solid. ¹H NMR (500 MHz, Chloroform-*d*) δ 11.07 (s, 1H), 8.23 (d, *J* = 8.6 Hz, 1H), 7.79 (d, *J* = 8.6 Hz, 1H), 7.19

– 7.13 (m, 2H), 7.07 – 7.00 (m, 1H), 4.35 – 4.24 (m, 2H), 3.99 (t, $J = 6.5$ Hz, 2H), 2.83 (s, 3H), 1.82 – 1.72 (m, 2H), 1.56 – 1.42 (m, 2H), 1.30 (t, $J = 7.2$ Hz, 3H), 0.97 (t, $J = 7.4$ Hz, 3H). MS (ESI) m/z 439.2 $[M+H]^+$.

5 Example 10

1-(5-Butoxy-2-fluorophenyl)-N-ethyl-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxamide



(a) 1-(5-Butoxy-2-fluorophenyl)-4-chloro-N-ethyl-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxamide

[0033] To a solution of 1-(5-butoxy-2-fluorophenyl)-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxylic acid (25 mg, 0.061 mmol) in CH_2Cl_2 (0.75 mL) is added thionyl chloride (45 μL , 0.62 mmol), followed by two drops of DMF. After stirring at 46 °C overnight, the reaction mixture is evaporated to dryness under reduced pressure. The residue is dissolved in CH_2Cl_2 (0.80 mL), and then ethanamine is bubbled through the solution at room temperature for 30 min. After the solvent is removed under reduced pressure, the residue is washed with water twice times (2×1 mL), and then dried under vacuum to give 26 mg of crude 1-(5-butoxy-2-fluorophenyl)-4-chloro-N-ethyl-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxamide, which is used in the next step without further purification. MS (ESI) m/z 456.2 $[M+H]^+$.


(b) 1-(5-Butoxy-2-fluorophenyl)-N-ethyl-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxamide

[0034] A suspension of 1-(5-butoxy-2-fluorophenyl)-4-chloro-N-ethyl-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxamide (26 mg, 0.057 mmol) and concentrated hydrochloric acid (10 μL) in dioxane (0.50 mL) in a sealed vial is heated in a microwave reactor at 130 °C for 1 h. After cooled to room temperature, the mixture is evaporated to dryness under reduced pressure. The obtained crude product is purified with a semi-preparative HPLC to give 1-(5-butoxy-2-

fluorophenyl)-N-ethyl-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxamide (11 mg, 44% yield) as a pale yellow solid. ¹H NMR (500 MHz, Chloroform-*d*) δ 10.77 (s, 1H), 8.30 (d, *J* = 8.5 Hz, 1H), 7.81 (d, *J* = 8.6 Hz, 1H), 7.26 – 7.16 (m, 2H), 7.13 – 7.06 (m, 1H), 6.84 – 6.76 (m, 1H), 4.10 – 3.90 (m, 2H), 3.42 – 3.24 (m, 2H), 2.83 (s, 3H), 1.87 – 1.72 (m, 2H), 1.55 – 1.42 (m, 2H), 1.11 (t, *J* = 7.3 Hz, 3H), 0.97 (t, *J* = 7.4 Hz, 3H). MS (ESI) *m/z* 438.2 [M+H]⁺.

Example 11


1-(5-Butoxy-2-fluorophenyl)-3-methyl-4-oxo-3a,4-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxamide



[0035] To a suspension of 1-(5-butoxy-2-fluorophenyl)-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carbonitrile (10 mg, 0.026 mmol) in dioxane (0.2 mL) is added 6N NaOH aqueous solution (40 μ L). The reaction mixture is heated at 100 °C for 2h. After cooled to room temperature, the reaction mixture is evaporated to dryness under reduced pressure. The residue is purified with a semi-preparative HPLC system to give 1-(5-butoxy-2-fluorophenyl)-3-methyl-4-oxo-3a,4-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxamide (3.2 mg, 30% yield) as an off white solid. ¹H NMR (500 MHz, Chloroform-*d*) δ 10.13 (s, 1H), 8.29 (d, *J* = 8.4 Hz, 1H), 7.76 (d, *J* = 8.3 Hz, 1H), 7.25 – 7.14 (m, 2H), 7.10 – 7.02 (m, 1H), 6.59 (s, 1H), 5.32 (s, 1H), 3.99 (t, *J* = 6.5 Hz, 2H), 2.81 (s, 3H), 1.82 – 1.74 (m, 2H), 1.52 – 1.46 (m, 2H), 0.97 (t, *J* = 7.4, 7.4 Hz, 3H). MS (ESI) *m/z* 410.2 [M+H]⁺.

Example 12

8-Chloro-1-(2-chloro-5-(cyclopropylmethoxy)phenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one



(a) 5-(Benzyloxy)-2-chlorobenzeneamine

[0036]

- A mixture of 4-chloro-5-nitrophenol (2.25 g, 13.0 mmol), (bromomethyl)benzene (2.33 g, 13.6 mmol) and cesium carbonate (8.50 g, 25.9 mmol) in anhydrous *N,N*-Dimethylacetamide (10 mL) is stirred at room temperature for 2 h. After the solvent is removed under reduced pressure, the residue is treated with water (300 mL) and then extracted with methylene three times (3 × 30 mL). The combined organic phase is evaporated to dryness to give 4-(benzyloxy)-1-chloro-2-nitrobenzene as an oil. To a solution of the crude 4-(benzyloxy)-1-chloro-2-nitrobenzene in EtOH (10 mL) is slowly added concentrated HCl (8 mL). The mixture is stirred at room temperature for 5 min, and then tin(II) chloride (8.0 g, 42.0 mmol) is added. After stirring at room temperature for 0.5 h, the reaction mixture is treated with water (400 mL) and then extracted with methylene (4 × 30 mL). The combined organic phase is washed with saturated NaHCO₃ (30 mL) and brine (30 mL) successively, and then evaporated to dryness to give 3.0 g of 5-(benzyloxy)-2-chlorobenzeneamine as light orange solid. MS (ESI) *m/z* 234.1 [M+H]⁺.

(b) (5-(Benzyloxy)-2-chlorophenyl)hydrazine

[0037]

- A solution of sodium nitrite (226 mg, 3.28 mmol) in water (3 mL) is added dropwise to a suspension of 5-(benzyloxy)-2-chlorobenzeneamine (640 mg, 2.74 mmol) in concentrated hydrochloric acid (5 mL) at 0°C. After the completion of the addition, the reaction mixture is stirred at 0 °C for 30 min. A solution of tin (II) chloride (2.08 g, 11.0 mmol) in concentrated hydrochloric acid (3 mL) is added. The resulting suspension is stirred at room temperature for 2 h, and then filtered. The filter cake is collected. The filtrate is basified to pH 10 with 10 N NaOH, and then extracted with CH₂Cl₂ (3 × 40 mL). The combined organic phase is evaporated to dryness. The obtained residue and the collected filter cake are combined and purified with a neutral aluminum oxide column using a gradient of 0 – 20% methanol in ethyl acetate to give (5-(benzyloxy)-2-chlorophenyl)hydrazine (300 mg, 44% yield). MS (ESI) *m/z* 249.1 [M+H]⁺.

(c) 8-Chloro-1-(2-chloro-5-hydroxyphenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one


[0038] To a suspension of (5-(benzyloxy)-2-fluorophenyl)hydrazine (650 mg, 2.6 mmol) and 3-acetyl-6-bromo-4-hydroxy-1,5-naphthyridin-2(1H)-one (200 mg, 0.71 mmol) in dioxane (2 mL) is added concentrated HCl (0.1 mL). The reaction mixture in a sealed tube is stirred at room temperature for 5 min and then heated at 110 °C for 2 days. After cooling to room temperature, the reaction mixture is treated with water (200 mL) and then extracted with CH₂Cl₂/MeOH (10/1) (4 × 50 mL). The combined organic phase is evaporated to dryness to give 409 mg of crude 8-chloro-1-(2-chloro-5-hydroxyphenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one, which is used directly in next step without further purification. A small amount of the crude product is purified with a semi-preparative HPLC for structural verification. ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.70 (s, 1H), 10.13 (s, 1H), 7.77 (d, *J* = 8.7 Hz, 1H), 7.54 (d, *J* = 8.7 Hz, 1H), 7.47 – 7.41 (m, 1H), 7.02 – 6.95 (m, 2H), 2.60 (s, 3H). MS (ESI) *m/z* 361.0 [M+H]⁺.

(d) 8-Chloro-1-(2-chloro-5-(cyclopropylmethoxy)phenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one

[0039] A suspension of 8-chloro-1-(2-chloro-5-hydroxyphenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one (60 mg, 0.17 mmol), (bromomethyl)cyclopropane (30 μL, 0.27 mmol) and sodium carbonate (36 mg, 0.23 mmol) in DMF (1.2 mL) in a sealed reaction vial is heated at 100 °C for 2 days. After cooled to room temperature, the reaction mixture is filtered. The filtrate is separated with a semi-preparative HPLC system using a gradient of 0 – 63% acetonitrile in water containing 0.1% formic acid over 16 min to give 8-chloro-1-(2-chloro-5-(cyclopropylmethoxy)phenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one as an off-white solid (7 mg, 10% yield). ¹H NMR (500 MHz, Chloroform-*d*) δ 11.08 (s, 1H), 7.71 (d, *J* = 8.6 Hz, 1H), 7.46 (d, *J* = 8.6 Hz, 1H), 7.38 (d, *J* = 8.6 Hz, 1H), 7.14 – 7.06 (m, 2H), 3.86 (dd, *J* = 7.0, 2.8 Hz, 2H), 2.83 (s, 3H), 1.37 – 1.24 (m, 1H), 0.73 – 0.62 (m, 2H), 0.44 – 0.29 (m, 2H). MS (ESI) *m/z* 415.1 [M+H]⁺.

Example 13


1-(2,5-Dichlorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one



- [0040]** To a suspension of 2,5-dichlorophenylhydrazine (80 mg, 0.45 mmol) and 3-acetyl-4-hydroxy-1,5-naphthyridin-2(1H)-one (62 mg, 0.30 mmol) in ethanol (2 mL) is added concentrated HCl (0.1 mL). The reaction mixture in a sealed tube is heated in a microwave reactor at 160 °C for 5 h. After cooled to room temperature, the reaction mixture is diluted with DMF (10 mL) and then filtered. The filtrate is isolated with a semi-preparative HPLC system to give 1-(2,5-Dichlorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one (20 mg, 50% yield:). ¹H NMR (500 MHz, Chloroform-*d*) δ 9.95 (s, 1H), 8.27 (dd, *J* = 4.5, 1.4 Hz, 1H), 7.66 – 7.56 (m, 2H), 7.52 – 7.43 (m, 2H), 7.37 (dd, *J* = 8.3, 4.5 Hz, 1H), 2.81 (s, 3H). MS (ESI) *m/z* 345.0 [M+H]⁺.

Example 14


- 1-(2-Chlorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one**



- [0041]** The title compound is prepared in an analogous fashion following the procedure described in the synthesis of Example 13 wherein (2-chlorophenyl)hydrazine is added instead of 2,5-dichlorophenylhydrazine. ¹H NMR (500 MHz, Chloroform-*d*) δ 10.22 (s, 1H), 8.24 (dd, *J* = 4.5, 1.4 Hz, 1H), 7.64 (dd, *J* = 8.3, 1.4 Hz, 1H), 7.61 – 7.53 (m, 2H), 7.52 – 7.42 (m, 2H), 7.34 (dd, *J* = 8.3, 4.5 Hz, 1H), 2.82 (s, 3H). MS (ESI) *m/z* 311.1 [M+H]⁺.

Example 15


- 1-(2-Chlorophenyl)-3,5-dimethyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one**



[0042] To a stirred suspension of sodium hydride (24 mg, 0.10 mmol) in DMF (0.60 mL) is added 1-(2-chlorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one (12 mg, 0.039 mmol). After the suspension is stirred at room temperature for 0.5 h, methyl iodide (274 mg, 1.93 mmol) is added. The mixture is stirred at room temperature for 1 h, and then cooled to -70 °C. Water (1 mL) is added to quench the reaction, followed by adding DMF (5 mL). The resulting mixture is filtered and the filtrate is isolated with a semi-preparative HPLC system to afford 1-(2-Chlorophenyl)-3,5-dimethyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one (12 mg, 72% yield). ¹H NMR (500 MHz, Chloroform-*d*) δ 8.22 (dd, *J* = 4.6, 1.2 Hz, 1H), 7.67 (dd, *J* = 8.6, 1.0 Hz, 1H), 7.59 – 7.53 (m, 2H), 7.51 – 7.41 (m, 2H), 7.38 (dd, *J* = 8.6, 4.2 Hz, 1H), 3.73 (s, 3H), 2.80 (s, 3H). MS (ESI) *m/z* 325.1 [M+H]⁺.

Example 16

15 **1-(2,5-Dichlorophenyl)-3,5-dimethyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one**




[0043] The title compound is prepared in an analogous fashion following the procedure described in the synthesis of Example 15 wherein 1-(2,5-dichlorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one is added instead of 1-(2-chlorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one. ¹H NMR (500 MHz, Chloroform-*d*) δ 8.27 (dd, *J* = 4.5, 1.4 Hz, 1H), 7.71 (dd, *J* = 8.7, 1.2 Hz, 1H), 7.60 (d, *J* = 2.2 Hz, 1H), 7.53 – 7.46 (m, 2H), 7.44 (dd, *J* = 8.6, 4.4 Hz, 1H), 3.76 (s, 3H), 2.81 (s, 3H). MS (ESI) *m/z* 359.0 [M+H]⁺.

25

Example 17


1-(5-Butoxy-2-chlorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one



[0044] The title compound is prepared in an analogous fashion following the procedure described in the synthesis of Example 13 wherein (5-butoxy-2-chlorophenyl)hydrazine is added instead of 2,5-dichlorophenylhydrazine. MS (ESI) m/z 383.2 $[M+H]^+$.

Example 18


1-(5-Butoxy-2-fluorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one



[0045] The title compound is prepared in an analogous fashion following the procedure described in the synthesis of Example 13 wherein (5-butoxy-2-fluorophenyl)hydrazine is added instead of 2,5-dichlorophenylhydrazine. 1H NMR (500 MHz, Chloroform- d) δ 10.69 (s, 1H), 8.32 (dd, J = 4.6, 1.4 Hz, 1H), 7.69 (dd, J = 8.4, 1.5 Hz, 1H), 7.37 (dd, J = 8.3, 4.5 Hz, 1H), 7.21 – 7.07 (m, 2H), 7.04 – 6.96 (m, 1H), 3.98 (t, J = 6.5 Hz, 2H), 2.82 (s, 3H), 1.84 – 1.68 (m, 2H), 1.56 – 1.42 (m, 2H), 0.97 (t, J = 7.4 Hz, 3H). MS (ESI) m/z 367.2 $[M+H]^+$.

Example 19


8-Chloro-1-(2,5-dichlorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one



[0046] The title compound is prepared in an analogous fashion following the procedure described in the synthesis of Example 13 wherein 3-acetyl-6-bromo-4-hydroxy-1,5-naphthyridin-2(1H)-one is added instead of 3-acetyl-4-hydroxy-1,5-naphthyridin-2(1H)-one. ¹H NMR (500 MHz, Chloroform-*d*) δ 10.94 (s, 1H), 7.67 (d, *J* = 8.6 Hz, 1H), 7.58 (d, *J* = 2.3 Hz, 1H), 7.55 – 7.46 (m, 2H), 7.38 (d, *J* = 8.5 Hz, 1H), 2.81 (s, 3H). MS (ESI) *m/z* 379.0 [M+H]⁺.

Example 20


1-(5-Butoxy-2-chlorophenyl)-8-chloro-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one



[0047] The title compound is prepared in an analogous fashion following the procedure described in the synthesis of Example 13 wherein (5-butoxy-2-chlorophenyl)hydrazine and 3-acetyl-6-bromo-4-hydroxy-1,5-naphthyridin-2(1H)-one are added instead of 2,5-dichlorophenylhydrazine and 3-acetyl-4-hydroxy-1,5-naphthyridin-2(1H)-one. ¹H NMR (500 MHz, Chloroform-*d*) δ 10.83 (s, 1H), 7.66 (d, *J* = 8.6 Hz, 1H), 7.43 (d, *J* = 8.9 Hz, 1H), 7.36 (d, *J* = 8.5 Hz, 1H), 7.09 (d, *J* = 2.9 Hz, 1H), 7.04 (dd, *J* = 8.9, 2.9 Hz, 1H), 3.99 (dt, *J* = 14.3, 7.0 Hz, 2H), 2.81 (s, 3H), 1.91 – 1.71 (m, 2H), 1.56 – 1.40 (m, 2H), 0.97 (t, *J* = 7.4 Hz, 3H). MS (ESI) *m/z* 417.1 [M+H]⁺.

Example 21


1-(5-Butoxy-2-chlorophenyl)-8-methoxy-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one



- [0048]** To a solution of 1-(5-butoxy-2-chlorophenyl)-8-chloro-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one (50 mg, 0.12 mmol) in dioxane (2.0 mL) is added sodium methoxide solution (0.5 N, 1 mL in MeOH), followed by adding
- 5 NaH (60 mg, 2.5 mmol) in portions under argon. The mixture is stirred at room temperature for 10 min and then heated in a sealed tube in a microwave reactor at 160 °C for 6 h. After the reaction mixture is cooled to room temperature, additional sodium methoxide solution (0.5 N, 0.8 mL in MeOH) and NaH (80 mg, 3.3 mmol) are added. The reaction vial is sealed and heated in a microwave reactor at 160 °C for
- 10 another 6 h. The mixture is cooled to room temperature, quenched with water (100 mL), and then extracted with CH₂Cl₂ (4 × 25 mL). The combined organic phase is evaporated to dryness under reduced pressure. The obtained residue is purified with a semi-preparative HPLC system using a gradient of 0 – 70% acetonitrile in water containing 0.1% formic acid over 16 min to give 1-(5-butoxy-2-chlorophenyl)-8-
- 15 methoxy-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one as an off-white solid (36 mg, 72% yield). ¹H NMR (500 MHz, Chloroform-*d*) δ 10.82 (s, 1H), 7.65 (d, *J* = 8.8 Hz, 1H), 7.41 (d, *J* = 8.9 Hz, 1H), 7.12 (d, *J* = 2.8 Hz, 1H), 6.98 (dd, *J* = 8.9, 2.8 Hz, 1H), 6.87 (d, *J* = 8.8 Hz, 1H), 4.08 – 3.88 (m, 2H), 3.36 (s, 3H), 2.82 (s, 3H), 1.83 – 1.69 (m, 2H), 1.55 – 1.39 (m, 2H), 0.96 (t, *J* = 7.4 Hz, 3H). MS (ESI) *m/z*
- 20 413.1 [M+H]⁺.

Example 22

1-(2-Chloro-5-(cyclobutylmethoxy)phenyl)-8-methoxy-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one



(a) 8-Chloro-1-(2-chloro-5-(cyclobutylmethoxy)phenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one

[0049] The title compound is prepared in an analogous fashion following the procedure described in the synthesis of Example 13 wherein (2-chloro-5-(cyclobutylmethoxy)phenyl)hydrazine and 3-acetyl-6-bromo-4-hydroxy-1,5-naphthyridin-2(1H)-one are added instead of 2,5-dichlorophenylhydrazine and 3-acetyl-4-hydroxy-1,5-naphthyridin-2(1H)-one.

(b) 1-(2-Chloro-5-(cyclobutylmethoxy)phenyl)-8-methoxy-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one

[0050] To a solution of crude 8-chloro-1-(2-chloro-5-(cyclobutylmethoxy)-phenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one (50 mg, 0.11 mmol) in methanol (1.5 mL) is added sodium methoxide solution (5M, 1 mL in MeOH), followed by adding CuI (22 mg, 0.12 mmol) under argon. The mixture is heated in a sealed tube in a microwave reactor at 130 °C for 1.5 h. The reaction mixture was cooled to room temperature, quenched with water (20 mL), and then extracted with ethyl acetate (20 mL). The combined organic phase is evaporated to dryness under reduced pressure. The obtained residue is purified with a semi-preparative HPLC system using a gradient of 0 – 43% acetonitrile in water containing 0.1% formic acid over 16 min to give 1-(2-Chloro-5-(cyclobutylmethoxy)phenyl)-8-methoxy-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one as a white solid (14 mg, 30% yield). ¹H NMR (500 MHz, Chloroform-*d*) δ 10.67 (s, 1H), 7.62 (d, *J* = 8.9 Hz, 1H), 7.41 (d, *J* = 8.9 Hz, 1H), 7.13 (d, *J* = 2.9 Hz, 1H), 6.98 (dd, *J* = 8.9, 2.9 Hz, 1H), 6.86 (d, *J* = 8.9 Hz, 1H), 3.97 – 3.90 (m, 2H), 3.36 (s, 3H), 2.82 (s, 3H), 2.79 – 2.72 (m, 1H), 2.16 – 2.09 (m, 2H), 1.99 – 1.90 (m, 2H), 1.88 – 1.81 (m, 2H). MS (ESI) *m/z* 425.1 [M+H]⁺.

EXAMPLE 23

Measurement of PDE2 inhibition *in vitro*

[0051] **r-hPDE2A** (Accession No. NM_002599, Homo sapiens phosphodiesterase 2A, cGMP-stimulated, transcript variant 1) A mammalian expression cloning vector with recombinant cDNA copy of the gene is purchased from Origene. Protein is expressed via transient transfection of HEK293 cells. The cells are harvested at 48 hours after transfection, washed once with TBS buffer

(50mM Tris-HCl, pH 7.5, 150 mM NaCl), then lysed by sonication in cold homogenization buffer (50 mM Tris-HCl, pH 7.5, 5 mM MgCl₂, 1X protease inhibitor cocktail). The homogenate is centrifuged for 30 min at 15,000 g at 4°C to obtain the soluble cytosolic fraction. The protein concentration of the cytosol is determined using BCA Protein Assay Kit (Pierce) with bovine serum albumin as a standard.

[0052] **Assay:** PDE2A is assayed with FL-cAMP as substrate. An enzyme titration is first performed to determine the working concentration of PDE. The concentration of the enzyme giving activity of 100 ΔmP in the absence of inhibitor is deemed an appropriate working concentration for PDE.

[0053] PDE enzyme is diluted in a standard reaction buffer (10mM Tris-HCl pH 7.2, 10mM MgCl₂, 0.1% BSA, 0.05% NaN₃) according to the titration curve. For PDE2 assay the reaction buffer is supplemented with 1μM cGMP to fully activate the enzyme. 99 μl of diluted enzyme solution is added into each well in a flat bottom 96-well polystyrene plate and then ~1 μl of test compound dissolved in 100% DMSO is added. The compounds are mixed and pre-incubated with the enzyme for 10 min at room temperature.

[0054] The FL-cNMP conversion reaction is initiated by addition of substrate (45 nM final). Enzyme and inhibitor mix (16 μl) and substrate solution (4 μl of 0.225 μM) are combined in a 384-well microtiter plate. The reaction is incubated in the dark at room temperature for 15 min. The reaction is halted by addition of 60 μl of binding reagent (1:400 dilution of IMAF beads in binding buffer supplemented with 1:1800 dilution of antifoam) to each well of the 384-well plate. The plate is incubated at room temperature for 1 hour to allow IMAF binding to proceed to completion, and then placed in an Envision multimode microplate reader (PerkinElmer, Shelton, CT) to measure the fluorescence polarization (Δmp).

[0055] A decrease in cAMP concentration, measured as decreased Δmp, is indicative of inhibition of PDE activity. IC₅₀ values are determined by measuring enzyme activity in the presence of 8 to 16 concentrations of compound ranging from 0.00037 nM to 80,000 nM and then plotting drug concentration versus Δmp. Test well values are normalized to control reactions run on the same plate (values converted to % of control). IC₅₀ values are estimated using nonlinear regression software, fitting a four-parameter one-site dose-response model (XLFit; IDBS, Cambridge, MA). Bottom of curve is fixed at 0% of control.

[0056] Quality Controls: To determine the IC₅₀ of an inhibitor, an enzyme concentration that gave optimal signal range of 100-200 milli-polarization units is selected. The total fluorescence intensity of each sample well is measured to calculate the average and standard deviation. If the total fluorescence intensity of any sample well is not within the range of Average \pm 3SD, the mp value of that particular well is discarded.

[0057] Using the IMAP procedure described or similarly described above, we screened a proprietary PDE-focused compound library to identify novel compounds with nanomolar PDE2 inhibitory activities. The exemplified compounds of the Disclosure (e.g. compounds of Examples 1-22) are tested and shown to generally have an IC₅₀ value of less than 2 μ M, majority of the compounds having an IC₅₀ value of less than or equal to 250 nM, most compounds less than 100nM, some less than 10nM. In particular, the IC₅₀ values of Bay 60-7550 and Examples 17, 19, 20, 21 and 22 are shown below.

Example	PDE2 IC ₅₀ (μ M)
Bay 60-7550	0.001
19	0.073
20	0.012
17	0.028
21	0.0094
22	0.0059

EXAMPLE 24

Pharmacokinetic Study in Mice

[0058] Mice are given a single oral dose of the compound of Example 22 (10mg/kg, PO) and plasma and brain availability are measured (0.25-4h) using HPLC and LC-MS using methods analogous to those described in Zhao et al., *J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci.* (2005) **819**(1):73-80 and Appels, N.M., et al., *Rapid Commun. Mass Spec.* 2005. **19**(15): p. 2187-92. The experiment shows that the compound of Example 22 has good brain access as shown in the table below compared to the published standard Bay 60-7550, which has a C_{max} of 3ng/ml; T_{max} of 0.25h and a blood to plasma ratio of 0.04 at 10mg/kg PO.

PK Parameters	Description	Ex. 22 10mg/kg PO Brain	Blood/plasma Ratio
E Half-life	hr	2.4	
C _{max} (obs)	ng/ml	17	1.4
T _{max} (obs)	hr	2.0	

AUC (0-4hr) (obs area)	ng-hr/ml	50	1.4
AUC (area)	ng-hr/ml	83	0.9

EXAMPLE 25**Measurements of cGMP in mouse brain in vivo:**

[0059] Mice are given a single intraperitoneal (i.p.) dose of the compound of Example 22 (3mg/kg) or BAY 60-7550 (3mg/kg) then killed by focused microwave irradiation of the head 15, 30, or 60 min later, as indicated in Figure 1. Striatum are dissected from the mouse brains and assayed for levels of cGMP. Trichloroacetic acid (TCA) is added to tissue samples for a final concentration of 5% TCA and the tissue is immediately sonicated in solution and stored on ice. The sonicated sample is centrifuged at 15,000 $\times g$ for 20 min at 4°C to remove the precipitated protein. To extract the TCA, the sample is washed three times in water saturated ether. The samples are then dried under vacuum (Speedvac, Savant SPD111V) at room temperature and re-suspended in 100 μ L EIA buffer. Both the samples and the cGMP serial diluted standards are acetylated using 0.64 M KOH and 4% acetic anhydride to increase the affinity of the cGMP antibody. Each sample is tested in duplicate in precoated assay plates alongside the 8-point cGMP standard dilutions. In addition, blank, maximum binding (B_0) and non-specific binding wells are included. To all wells containing 50 μ L sample or standard, equal volumes of AChE-linked cGMP and cGMP antibody are added. The plate is incubated at 4°C for 18 hours. The wells are then washed 5 times with wash buffer. Detection reagent containing acetylthiocholine and 2-nitrobenzoic acid is added and the plate is incubated at room temperature until the OD of the B_0 wells is at least 0.5 as recorded by the SoftMax 4.8 software (Molecular Devices, Sunnyvale, CA). Each data point is converted to % B/ B_0 ($100 \times [(\text{sample or standard OD} - \text{average non-specific binding}) / (\text{average } B_0 - \text{average non-specific binding})]$). The standards are plotted and fit to a 4-parameter logistic equation (Figure 1). The concentrations of the samples are interpolated from the standard curve using Microsoft Excel and GraphPad Prism.


[0060] Using the procedure as described or similarly described above, the experiment shows that the compound of Example 22 increases cGMP levels in the striatum of mice after systemic dosing compared to Bay 60-7550 (See Figure 1), which shows improvement in brain access of the compound of Example 22 compared to Bay60-7550.

PAGE RECEIVED BLANK UPON FILING

CLAIMS

What is claimed is:

1. A Compound of Formula I




Formula I

wherein

- (i) R_1 is C_{1-4} alkyl (e.g., methyl);
- (ii) R_2 is selected from the group consisting of:
 - H,
 - OH,
 - halo (e.g., chloro),
 - C_{1-4} alkyl (e.g., methyl),
 - C_{1-4} alkoxy (e.g., methoxy or ethoxy),
 - N(R_f)(R_g),
 - C(O)N(R_h)(R_i),
 - C(O)OR_j,
 - CN,
 - C_{1-4} alkylthio (e.g., ethylthio),
 - heteroaryl (e.g., pyrazolyl, e.g., pyrazol-1-yl),
 - heteroC₃₋₇cycloalkyl (e.g., morpholinyl (e.g., morpholin-1-yl) or pyrrolidinyl (e.g., pyrrolidin-1-yl)), and
 - aryloxy (e.g., phenoxy) wherein said aryl is optionally substituted with one or more halo (e.g., fluoro), for example 4-fluorophenoxy;
- (iii) R_3 is H or C_{1-4} alkyl (e.g., methyl);

- (iv) R_a , R_b , R_c , R_d and R_e are independently H, halo (e.g., chloro or fluoro), -O- C_{1-6} alkyl (e.g., propoxy, butoxy (e.g., n-butoxy, isobutoxy), -OCH₂-cyclopropyl, -OCH₂-cyclobutyl or -OCH₂-cyclopentyl);
- (v) R_f and R_g are independently H, C_{1-4} alkyl (e.g., methyl) or heteroaryl (e.g., pyridyl (e.g., pyrid-2-yl));
- (vi) R_h and R_i are independently H or C_{1-4} alkyl (e.g., ethyl);
- (vii) R_j is H or C_{1-4} alkyl (e.g., ethyl);
- in free or salt form.

2. The compound according to claim 1, wherein the compound is Formula I(i):



in free or salt form.

3. The compound according to claim 1 or 2, wherein:
- (i) R_1 is C_{1-4} alkyl (e.g., methyl);
- (ii) R_2 is C_{1-4} alkoxy (e.g., methoxy or ethoxy);
- (iii) R_3 is H;
- (iv) R_b , R_c and R_e are H; R_a is halo and R_d is -O- C_{1-6} alkyl (e.g., propoxy, butoxy (e.g., n-butoxy, isobutoxy), -OCH₂-cyclopropyl, -OCH₂-cyclobutyl or -OCH₂-cyclopentyl);
- in free or salt form.
4. The compound according to claim 1 or 2, wherein the compound is selected from the group consisting of:
- 1-(5-Butoxy-2-fluorophenyl)-8-(4-fluorophenoxy)-3-methyl-1*H*-pyrazolo[4,3-*c*][1,5]naphthyridin-4(5*H*)-one;

- 1-(5-Butoxy-2-fluorophenyl)-8-(dimethylamino)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
- 1-(5-Butoxy-2-fluorophenyl)-3-methyl-8-(pyrrolidin-1-yl)-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
- 5 1-(5-Butoxy-2-fluorophenyl)-3-methyl-8-(1H-pyrazol-1-yl)-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
- 1-(5-Butoxy-2-fluorophenyl)-3-methyl-8-(pyridin-2-ylamino)-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
- 1-(5-Butoxy-2-fluorophenyl)-8-(ethylthio)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
- 10 1-(5-Butoxy-2-fluorophenyl)-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carbonitrile;
- 1-(5-Butoxy-2-fluorophenyl)-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxylic acid;
- 15 Ethyl 1-(5-butoxy-2-fluorophenyl)-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxylate;
- 1-(5-Butoxy-2-fluorophenyl)-N-ethyl-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxamide;
- 1-(5-Butoxy-2-fluorophenyl)-3-methyl-4-oxo-3a,4-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxamide;
- 20 8-Chloro-1-(2-chloro-5-(cyclopropylmethoxy)phenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
- 1-(2,5-Dichlorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
- 25 1-(2-Chlorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
- 1-(2-Chlorophenyl)-3,5-dimethyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
- 1-(2,5-Dichlorophenyl)-3,5-dimethyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
- 30 1-(5-Butoxy-2-chlorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;
- 1-(5-Butoxy-2-fluorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;

8-Chloro-1-(2,5-dichlorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;

1-(5-Butoxy-2-chlorophenyl)-8-chloro-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;

5 1-(5-Butoxy-2-chlorophenyl)-8-methoxy-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one; and

1-(2-Chloro-5-(cyclobutylmethoxy)phenyl)-8-methoxy-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one;

in free or salt form.

10

5. A pharmaceutical composition comprising a compound according to any of claims 1-4, in combination or association with a pharmaceutically acceptable diluents or carrier.

15

6. A method for the treatment of a PDE2 mediated disorder comprising administering to a subject in need thereof an effective amount of a compound according to any of claims 1-4 or a pharmaceutical composition according to claim 5.

20

7. The method of claim 6, wherein the disorder is selected from the group consisting of neurological disorders (such as migraine; epilepsy; Alzheimer's disease; Parkinson's disease; brain injury; stroke; cerebrovascular diseases (including cerebral arteriosclerosis, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, and brain hypoxia-ischemia); spinal muscular atrophy; lateral sclerosis; multiple sclerosis; cognitive disorders (including amnesia, senile dementia, HIV associated dementia, Alzheimer's associated dementia, Huntington's associated dementia, Lewy body dementia, vascular dementia, drug related dementia, delirium, and mild cognitive impairment); cognitive dysfunction associated with Parkinson's disease and depression; mental deficiency (including

25 Down syndrome and fragile X syndrome); sleep disorders (including hypersomnia, circadian rhythm sleep disorder, insomnia, parasomnia, and sleep deprivation); psychiatric disorders (such as anxiety (including acute stress disorder, generalized anxiety disorder, social anxiety disorder, panic disorder,

30

- post-traumatic stress disorder (PTSD), obsessive-compulsive disorder, specific phobia, social phobia, chronic anxiety disorder and obsessive compulsive disorder,); factitious disorder (including acute hallucinatory mania); impulse control disorders (including pathological gambling, pathological fire-setting, pathological stealing and intermittent explosive disorder); mood disorders (including bipolar I disorder, bipolar II disorder, mania, mixed affective state, major depression, chronic depression, seasonal depression, psychotic depression and postpartum depression); psychomotor disorders (extrapyramidal and movement disorders, e.g., Parkinsonism, Lewy body disease, tremor, drug-induced tremor, drug-induced tardive dyskinesia, L-dopa-induced dyskinesia and restless leg syndrome); psychotic disorders (including schizophrenia (e.g., continuous or episodic, paranoid, hebephrenic, catatonic, undifferentiated and residual schizophrenic disorders), schizoaffective disorder, schizophreniform, and delusional disorder); drug dependence (including narcotic dependence, alcoholism, amphetamine dependence, cocaine addiction, nicotine dependence, and drug withdrawal syndrome); eating disorders (including anorexia, bulimia, binge eating disorder, hyperphagia, and pagophagia); pediatric psychiatric disorders (including attention deficit disorder, attention deficit/hyperactive disorder, conduct disorder (e.g., tic disorders such as transient, chronic, motor or vocal tic disorders), autism and autism spectrum disorder (ASD)); mental and behavioral disorders due to psychoactive substance use; cardiovascular disorder (e.g., pulmonary hypertension and pulmonary arterial hypertension); and pain (e.g., bone and joint pain (osteoarthritis), repetitive motion pain, dental pain, cancer pain, myofascial pain (muscular injury, fibromyalgia), perioperative pain (general surgery, gynecological), chronic pain and neuropathic pain).
8. The method of claim 6 wherein the disorder is selected from the following: anxiety, depression, autism spectrum disorder, schizophrenia, anxiety and/or depression in autistic and/or schizophrenic patients, and cognitive impairment associated with schizophrenia or dementia.
9. The Compound according to any of claims 1-4, in free or pharmaceutically acceptable salt form, or a pharmaceutical composition according to claim 5 (for

use in the manufacture of a medicament) for the treatment or prophylactic treatment of a disease, disorder or condition according to any one of claims 6-8.


10. A pharmaceutical composition comprising the compound according to any of
5 claims 1-4, in free or pharmaceutically acceptable salt form, for use (in the manufacture of a medicament) for the treatment or prophylactic treatment of a disease, disorder or condition according to any one of claims 6-8.
11. A pharmaceutical composition comprising the compound according to any of
10 claims 1-4, in free or pharmaceutically acceptable salt form, for use as a medicament.

1/1

Figure 1

Brain cGMP levels (p<0.05 vs. control, ANOVA)

5



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US15/64331

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 5-11
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US15/64331

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 31/4375; C07D 471/14 (2016.01)

CPC - A61K 31/4375; C07D 471/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8): A61K 31/4375; C07D 471/14 (2015.01)

CPC: A61K 31/4375; C07D 471/14 USPC: 514/293, 406; 546/82

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PATSEER (US, EP, WO, JP, DE, GB, CN, FR, KR, ES, AU, IN, CA, Other Countries (INPADOC), RU, AT, CH, TH, BR, PH); EBSCO; Google Scholar; IP.com; SureChEMBL; KEYWORDS: pyrazolo naphthyridin*, naphthyridin 4 one, pyrazolo 4 3 c naphthyridin*, pyrazolo 4 3 c 1 5 naphthyridin 4 one, PDE* inhibit*, naphthyridin 4 5H one, Alzheimer*, schizophren*, pyrazolo pyridin 4 one, base form*

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2014/154586 A1 (SANOFI) 02 October 2014; page 3, lines 7-17; page 4, lines 22-24; page 5, lines 7-8; page 37, lines 10-13, 32-34	1-2, 3/1-2, 4/1-2
A	US 2009/0030003 A1 (VERHOEST, PR et al.) 29 January 2009; abstract; paragraphs [0016]-[0018], [0263]	1-2, 3/1-2, 4/1-2
A	US 2010/0093782 A1 (KANAZAWA, H et al.) 15 April 2010; abstract; paragraphs [0016]-[0020], [0064]	1-2, 3/1-2, 4/1-2
A	US 2012/0220624 A1 (SIU et al.) 30 August 2012; entire document	1-2, 3/1-2, 4/1-2

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

20 January 2016 (20.01.2016)

Date of mailing of the international search report

12 FEB 2016

Name and mailing address of the ISA/

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

摘要

本发明涉及如上所述的式 I 的新型 PDE2 抑制化合物、它们作为药物的用途和包含它们的药物组合物。

脑 cGMP 水平(与对照组相比, $p < 0.05$, ANOVA)

